Only way is down for Elan

Elan chief executive Kelly Martin’s contract includes $5m if Elan is sold this year and $3m if it goes next year, adding to doubts about the company’s survival after the announcement of a third patient death. BRIAN O'MAHONY reports.

Unless the group can find a way back quickly, analysts see its days as numbered

In the wake of the announcement of a third death linked to the MS drug Tysabri, Elan chief executive Kelly Martin has seen the company’s shares fall 56% on Thursday to $3.18 from a peak in 2001 of $65.